Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Aeterna: Final Phase 3 Results Show AEZS-130 Safe, Effective In Diagnosing AGHD

RELATED NEWS
Trade AEZS now with 

Aeterna Zentaris Inc. (AEZS: Quote, AEZ.TO) said that final Phase 3 results for its oral ghrelin agonist, AEZS-130, show that the drug is safe and effective in diagnosing adult growth hormone deficiency, or AGHD.

The multicenter open label study was originally designed as a cross-over trial of AEZS-130 vs growth hormone-releasing hormone (GHRH)+L-Arginine (ARG) in AGHD patients and in controls, matched for body mass index, estrogen status, gender and age. After 43 AGHD patients and 10 controls had been tested, GHRH became unavailable. The study was completed by testing 10 more AGHD patients and 38 controls with AEZS-130 alone.

The objective of the clinical trial was to determine the efficacy and safety of AEZS-130 in the diagnosis of AGHD.

Click here to receive FREE breaking news email alerts for AEterna Zentaris Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Ireland's economy grew for the second consecutive quarter in the three months to June, latest figures from the Central Statistics Office showed Thursday. Gross domestic product grew a seasonally adjusted 1.5 percent sequentially following 2.8 percent expansion in the first quarter, revised from 2.7... A historic referendum that decides the future of Scotland has begun. The Scots are voting Thursday on whether Scotland should become an independent country or stay in the United Kingdom. Voting opened at 7am local time in more than 2,600 polling stations, where voters are given the "Yes" and "No" options to the referendum question: "Should Scotland be an independent country?." More than four milli The European Central Bank announced Thursday the results of its first targeted longer term refinancing operation, or TLTRO, which is aimed to boost liquidity at Eurozone banks to help revive lending to small businesses and households. The central bank announced that 255 bidders were allotted EUR 82.60...
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.